Scientific Programme

11:00 - 11:30 Introduction and objectives of the meeting A. Antinori, A. d’Arminio Monforte
11:30 - 12:00 OPENING LECTURE
Chair: A. Lazzarin
  Milestones of ICONA advances of knowledge on HIV: a 25 years’ story A. d’Arminio Monforte

SESSION 1 - Real-Life Studies On Antiretroviral Therapy-1

Chairs: A. Lazzarin, E. Quiros-Roldan

REGISTRIES ON INDIVIDUAL REGIMENS AND ART EFFECTIVENESS

12:00 - 12:10 Real life study of PLWH initiating BIC/FTC/TAF as naïve or experienced A. Tavelli
12:10 - 12:20 Real life study on PLWH initiating 3TC-DTG as first line therapy S. Lo Caputo
12:20 - 12:30 Criteria of doravirine choice in naïve and experienced in the ICONA cohort A. Saracino
12:30 - 12:40 Changes of body weight and of plasma lipidome in PLWH starting double or triple INSTI regimens F. Bai
12:40 - 12:50 Predictors of starting dual DTG as naïve and experienced N. Gianotti, A. Vergori
12:50 - 13:00 EPICO Study: EPIdemiology and Comorbidities of people living with HIV (PLWH) SWITHCHing to current therapeutic strategies A. Cozzi-Lepri
13:00 - 13:20 Discussion
13:20 - 14:10 Lunch
14:10 - 15:10 ROUND TABLE: THE ROLE OF ICONA COHORT ON ANTIRETROVIRAL THERAPY IN 2023 AND BEYOND
Presenters: A. Castagna, F. Maggiolo
Discussants: C. Pinnetti, S. Rusconi, B. Suligoi
 

SESSION 2 - HIV And Coinfections

Chairs: G.V. Calvino, G. Guaraldi

LECTURES

15:10 - 15:25 COVID-19 and Monkeypox: what impacts on PLWH? A. Antinori
15:25 - 15:40 How anti-SARS-CoV-2 prophylaxis and therapy changed the natural course of COVID-19 C. Mussini
15:40 - 16:00 Discussion
 

COVID-19, MPX AND HIV: DATA FROM ICONA

16:00 - 16:10 Impact of COVID-19 on linkage to HIV care G. Madeddu
16:10 - 16:20 Impact of COVID-19 on viral suppression and retention to care R. Gagliardini
16:20 - 16:30 Monkeypox and the ICONA Cohort V. Mazzotta
16:30 - 17:00 Session key points and discussion on ICONA perspectives
M. Cernuschi, A. Giacomelli, S. Lanini
17:00 - 17:15 Coffee break
 

SESSION 3 - Hepatitis In The ICONA Cohort

Chairs: L. Sarmati

LECTURES

17:15 - 17:30 New strategies to get to zero hepatitis infections E. Girardi
17:30 - 17:45 Role of lab in detecting HDV-associated liver disease V. Svicher
17:45 - 18:00 Discussion
 

HBV, HDV, HCV: DATA FROM ICONA

18:00 - 18:10 Natural history of HDV infection in the ICONA cohort: candidates to new therapies M. Puoti
18:10 - 18:20 NoCo study: long-term follow-up A. d’Arminio Monforte
18:20 - 18:50 Session key points and discussion on ICONA perspectives
F. Ceccherini Silberstein, R. Rossotti

SESSION 4 - Anti-SARS CoV-2 Vaccine Outcomes In The ICONA Cohort

Chairs: S. Antinori. A. Gori, G. Rizzardini

LECTURE

08:45 - 09:00 New vaccines, new diseases: what in the present and in pipeline - C.F. Perno
09:00 - 09:10 Discussion
 

SARS-COV-2 VACCINES: DATA FROM ICONA

09:10 - 09:20 Humoral response to anti-SARS-CoV-2 vaccines: the Orchestra study A. Vergori
09:20 - 09:30 Cellular response to anti-SARS-CoV-2 vaccines: the Orchestra study G.C. Marchetti
09:30 - 10:00 Session key points and discussion on ICONA perspectives A. Bandera, A. Di Biagio
 

SESSION 5 - ICONA New Projects

Chairs: A. Castagna, F. Schlosser
10:00 - 10:10 First results from the App ‘e-QoL’ of ICONA cohort and next implementations A. Cingolani
10:10 - 10:20 ICONA XT: report of the events and suggestions for future initiatives for young researchers D. Barbanotti, A. d’Arminio Monforte
10:20 - 10:30 Long-ICONA: the project and a photo of the first included PLWH A. Rodanò
10:30 - 10:40 ICONA data: from the report to the newsletter S. Lo Caputo
10:40 - 11:10 Session key points and discussion on ICONA perspectives M.L. Cosmaro, M. Lichtner
11:10 - 11:25 Coffee break
 

SESSION 6 - Future Research Topics In The ICONA Cohort

ROUND TABLE - THE CURE AGENDA: WHAT POSSIBLE ICONA CONTRIBUTIONS

Chair: C.F. Perno
Presenters: A. Calcagno, F. Ceccherini Silberstein, G.C. Marchetti
Discussants: All members of Scientific Secretary of ICONA
 

SESSION 7 - Meeting Restricted To ICONA Centers

12:25 - 13:45 Discussion with centers I. Fanti, A. Rodanò, A. Tavelli, T. White
13:45 - 14:00 Closing Remarks A. Antinori, A. d’Arminio Monforte
×